Treatment resistant schizophrenia and response to antipsychotics: A review

Schizophrenia Research

Volumn 133, Issue 1-3, 2011, Pages 54-62

  Suzuki, Takefumi ^a,b,c   Remington, Gary ^a,b   Mulsant, Benoit H ^a,b   Rajji, Tarek K ^a   Uchida, Hiroyuki ^a,c   Graff Guerrero, Ariel ^a,b   Mamo, David C ^a,b  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c KEIO UNIVERSITY   (Japan)

Author keywords

Definition; Response; Treatment resistant schizophrenia

Indexed keywords

ARIPIPRAZOLE; CHLORPROMAZINE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; HERBACEOUS AGENT; NEUROLEPTIC AGENT; OLANZAPINE; ONDANSETRON; PERPHENAZINE; PLACEBO; QUETIAPINE; RISPERIDONE; SERTINDOLE; ZIPRASIDONE;

BRIEF PSYCHIATRIC RATING SCALE; CLINICAL GLOBAL IMPRESSION SCALE; COGNITION; DRUG RESPONSE; DRUG TREATMENT FAILURE; GINKGO BILOBA; HUMAN; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHIZOPHRENIA; SOCIAL STATUS; SYSTEMATIC REVIEW; TREATMENT RESISTANT SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; DATABASES, BIBLIOGRAPHIC; HUMANS; SCHIZOPHRENIA;

EID: 81955161935     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2011.09.016     Document Type: Review

References (73)

1. Agid O., Kapur S., Arenovich T., Zipursky R.B. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch. Gen. Psychiatry 2003, 60:1228-1235.
2. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 1994, American Psychiatric Association, Washington DC. 4th ed.
3. Andreasen N.C., Carpenter W.T., Kane J.M., Lasser R.A., Marder S.R., Weinberger D.R. Remission in schizophrenia: proposed criteria and rationale for consensus. Am. J. Psychiatry 2005, 162:441-449.
4. Azorin J.M., Spiegel R., Remington G., Vanelle J.M., Péré J.J., Giguere M., Bourdeix I. A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia. Am. J. Psychiatry 2001, 158:1305-1313.
5. Baldessarini R.J., Cohen B.M., Teicher M.H. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch. Gen. Psychiatry 1988, 45:79-91.
6. Bitter I., Dossenbach M.R., Brook S., Feldman P.D., Metcalfe S., Gagiano C.A., Füredi J., Bartko G., Janka Z., Banki C.M., Kovacs G., Breier A. Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2004, 28:173-180. Olanzapine HGCK Study Group.
7. Bondolfi G., Dufour H., Patris M., May J.P., Billeter U., Eap C.B., Baumann P. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group. Am. J. Psychiatry 1998, 155:499-504.
8. Bowie C.R., Depp C., McGrath J.A., Wolyniec P., Mausbach B.T., Thornquist M.H., Luke J., Patterson T.L., Harvey P.D., Pulver A.E. Prediction of real-world functional disability in chronic mental disorders: a comparison of schizophrenia and bipolar disorder. Am. J. Psychiatry 2010, 167:1116-1124.
9. Breier A., Hamilton S.H. Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia. Biol. Psychiatry 1999, 45:403-411.
10. Breier A., Buchanan R.W., Kirkpatrick B., Davis O.R., Irish D., Summerfelt A., Carpenter W.T. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am. J. Psychiatry 1994, 151:20-26.
11. Buchanan R.W., Kreyenbuhl J., Kelly D.L., Noel J.M., Boggs D.L., Fischer B.A., Himelhoch S., Fang B., Peterson E., Aquino P.R., Keller W., Schizophrenia Patient Outcomes Research Team (PORT) The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr. Bull. 2010, 36:71-93.
12. Chiu N.Y., Yang Y.K., Chen P.S., Chang C.C., Lee I.H., Lee J.R. Olanzapine in Chinese treatment-resistant patients with schizophrenia: an open-label, prospective trial. Psychiatry Clin. Neurosci. 2003, 57:478-484.
13. Ciapparelli A., Dell'Osso L., Bandettini di Poggio A., Carmassi C., Cecconi D., Fenzi M., Chiavacci M.C., Bottai M., Ramacciotti C.E., Cassano G.B. Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month follow-up study. J. Clin. Psychiatry 2003, 64:451-458.
14. Conley R.R., Tamminga C.A., Bartko J.J., Richardson C., Peszke M., Lingle J., Hegerty J., Love R., Gounaris C., Zaremba S. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am. J. Psychiatry 1998, 155:914-920.
15. Conley R.R., Kelly D.L., Nelson M.W., Richardson C.M., Feldman S., Benham R., Steiner P., Yu Y., Khan I., McMullen R., Gale E., Mackowick M., Love R.C. Risperidone, quetiapine, and fluphenazine in the treatment of patients with therapy-refractory schizophrenia. Clin. Neuropharmacol. 2005, 28:163-168.
16. Davis J.M., Chen N. Dose response and dose equivalence of antipsychotics. J. Clin. Psychopharmacol. 2004, 24:192-208.
17. Dossenbach M.R.K., Beuzen J.N., Avnon M., Belmaker R.H., Elizur A., Mark M., Munitz H., Schneidman M., Shoshani D., Kratky P., Grundy S.L., Tollefson G.D. The effectiveness of olanzapine in treatment-refractory schizophrenia when patients are nonresponsive to or unable to tolerate clozapine. Clin. Ther. 2000, 22:1021-1034.
18. Emsley R.A., Raniwalla J., Bailey P.J., Jones A.M. A comparison of the effects of quetiapine ('seroquel') and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. PRIZE Study Group. Int. Clin. Psychopharmacol. 2000, 15:121-131.
19. Flynn S.W., MacEwan G.W., Altman S., Kopala L.C., Fredrikson D.H., Smith G.N., Honer W.G. An open comparison of clozapine and risperidone in treatment-resistant schizophrenia. Pharmacopsychiatry 1998, 31:25-29.
20. Foussias G., Remington G. Negative symptoms in schizophrenia: avolition and Occam's razor. Schizophr. Bull. 2010, 36:359-369.
21. Gardner D.M., Murphy A.L., O'Donnell H., Centorrino F., Baldessarini R.J. International consensus study of antipsychotic dosing. Am. J. Psychiatry 2010, 167:686-693.
22. Guy W. ECDEU Assessment Manual for Psychopharmacology-Revised (DHEW Publ No ADM 76-338) 1976, 218-222. U.S. Department of Heath, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, Rockville, MD.
23. Harvey P.D., Bellack A.S. Toward a terminology for functional recovery in schizophrenia: is functional remission a viable concept?. Schizophr. Bull. 2009, 35:300-306.
24. Heinrichs D.W., Hanlon T.E., Carpenter W.T. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr. Bull. 1984, 10:388-398.
25. Hong C.J., Chen J.Y., Chiu H.J., Sim C.B. A double-blind comparative study of clozapine versus chlorpromazine on Chinese patients with treatment-refractory schizophrenia. Int. Clin. Psychopharmacol. 1997, 12:123-130.
26. Jäger M., Schmauss M., Laux G., Pfeiffer H., Naber D., Schmidt L.G., Gaebel W., Klosterkötter J., Heuser I., Maier W., Lemke M.R., Degner D., Buchkremer G., Gastpar M., Möller H.J., Riedel M. Early improvement as a predictor of remission and response in schizophrenia: results from a naturalistic study. Eur. Psychiatry 2009, 24:501-506.
27. Josiassen R.C., Joseph A., Kohegyi E., Stokes S., Dadvand M., Paing W.W., Shaughnessy R.A. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Am. J. Psychiatry 2005, 162:130-136.
28. Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry 1988, 45:789-796.
29. Kane J.M., Marder S.R., Schooler N.R., Wirshing W.C., Umbricht D., Baker R.W., Wirshing D.A., Safferman A., Ganguli R., McMeniman M., Borenstein M. Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison. Arch. Gen. Psychiatry 2001, 58:965-972.
30. Kane J.M., Khanna S., Rajadhyaksha S., Giller E. Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia. Int. Clin. Psychopharmacol. 2006, 21:21-28.
31. Kane J.M., Meltzer H.Y., Carson W.H., McQuade R.D., Marcus R.N., Sanchez R. Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine. J. Clin. Psychiatry 2007, 68:213-223. Aripiprazole Study Group.
32. Kane J.M., Potkin S.G., Daniel D.G., Buckley P.F. A double-blind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophrenia. J. Clin. Psychiatry 2011, 72:194-204.
33. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13:261-276.
34. Kinon B.J., Kane J.M., Johns C., Perovich R., Ismi M., Koreen A., Weiden P. Treatment of neuroleptic-resistant schizophrenic relapse. Psychopharmacol. Bull. 1993, 29:309-314.
35. Leifker F.R., Patterson T.L., Heaton R.K., Harvey P.D. Validating measures of real-world outcome: the results of the VALERO Expert Survey and RAND panel. Schizophr. Bull. 2011, 37:334-343.
36. Leon A.C. Implications of clinical trial design on sample size requirements. Schizophr. Bull. 2008, 34:664-669.
37. Lepping P., Sambhi R.S., Whittington R., Lane S., Poole R. Clinical relevance of findings in trials of antipsychotics: systematic review. Br. J. Psychiatry 2011, 198:341-345.
38. Leucht S., Kane J.M., Kissling W., Hamann J., Etschel E., Engel R.R. What does the PANSS mean?. Schizophr. Res. 2005, 79:231-238.
39. Leucht S., Kane J.M., Etschel E., Kissling W., Hamann J., Engel R.R. Linking the PANSS, BPRS, and CGI: clinical implications. Neuropsychopharmacology 2006, 31:2318-2325.
40. Leucht S., Busch R., Kissling W., Kane J.M. Early prediction of antipsychotic nonresponse among patients with schizophrenia. J. Clin. Psychiatry 2007, 68:352-360.
41. Leucht S., Davis J.M., Engel R.R., Kissling W., Kane J.M. Definitions of response and remission in schizophrenia: recommendations for their use and their presentation. Acta Psychiatr. Scand. Suppl. 2009, s438:7-14.
42. Levine S.Z., Leucht S. Elaboration on the early-onset hypothesis of antipsychotic drug action: treatment response trajectories. Biol. Psychiatry 2010, 68:86-92.
43. Lieberman J.A., Safferman A.Z., Pollack S., Szymanski S., Johns C., Howard A., Kronig M., Bookstein P., Kane J.M. Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am. J. Psychiatry 1994, 151:1744-1752.
44. Lindenmayer J.P., Volavka J., Lieberman J., Sheitman B., Citrome L., Chakos M., Czobor P., Parker B., Iskander A. Olanzapine for schizophrenia refractory to typical and atypical antipsychotics: an open-label, prospective trial. J. Clin. Psychopharmacol. 2001, 21:448-453.
45. Lindenmayer J.P., Czobor P., Volavka J., Lieberman J.A., Citrome L., Sheitman B., Chakos M., McEvoy J.P. Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study. J. Clin. Psychiatry 2002, 63:931-935.
46. Martin J.L., Pérez V., Sacristán M., Rodríguez-Artalejo F., Martínez C., Alvarez E. Meta-analysis of drop-out rates in randomised clinical trials, comparing typical and atypical antipsychotics in the treatment of schizophrenia. Eur. Psychiatry 2006, 21:11-20.
47. Meltzer H.Y. Duration of a clozapine trial in neuroleptic-resistant schizophrenia. Arch. Gen. Psychiatry 1989, 46:672.
48. Meltzer H.Y. Treatment-resistant schizophrenia - the role of clozapine. Curr. Med. Res. Opin. 1997, 14:1-20.
49. Meltzer H.Y., Bobo W.V., Roy A., Jayathilake K., Chen Y., Ertugrul A., Anil Yaǧcioǧlu A.E., Small J.G. A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia. J. Clin. Psychiatry 2008, 69:274-285.
50. Overall J.E., Gorham D.R. The brief psychiatric rating scale (BPRS): recent development in ascertainment and scaling. Psychopharmacol. Bull. 1988, 24:97-99.
51. Rabinowitz J., Levine S.Z., Barkai O., Davidov O. Dropout rates in randomized clinical trials of antipsychotics: a meta-analysis comparing first- and second-generation drugs and an examination of the role of trial design features. Schizophr. Bull. 2009, 35:775-788.
52. Remington G., Foussias G., Agid O. Progress in defining optimal treatment outcome in schizophrenia. CNS Drugs 2010, 24:9-20.
53. Rosenheck R., Cramer J., Xu W., Thomas J., Henderson W., Frisman L., Fye C., Charney D. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. N. Engl. J. Med. 1997, 337:809-815.
54. Sacchetti E., Galluzzo A., Valsecchi P., Romeo F., Gorini B., Warrington L. Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study. Schizophr. Res. 2009, 113:112-121. MOZART Study Group.
55. Semiz U.B., Cetin M., Basoglu C., Ebrinc S., Uzun O., Herken H., Balibey H., Algul A., Ates A. Clinical predictors of therapeutic response to clozapine in a sample of Turkish patients with treatment-resistant schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31:1330-1336.
56. Sherwood M., Thornton A.E., Honer W.G. A meta-analysis of profile and time-course of symptom change in acute schizophrenia treated with atypical antipsychotics. Int. J. Neuropsychopharmacol. 2006, 9:357-366.
57. Spina E., Avenoso A., Facciolà G., Scordo M.G., Ancione M., Madia A.G., Ventimiglia A., Perucca E. Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics. Psychopharmacology (Berl) 2000, 148:83-89.
58. Suzuki, T., in press. Which rating scales are regarded as 'the standard' in clinical trials for schizophrenia? A critical review. Psychopharmacol. Bull. http://www.medworksmedia.com/.
59. Suzuki T., Uchida H., Tanaka K.F., Tomita M., Tsunoda K., Nomura K., Takano H., Tanabe A., Watanabe K., Yagi G., Kashima H. Reducing the dose of antipsychotic medications for those who had been treated with high-dose antipsychotic polypharmacy: an open study of dose reduction for chronic schizophrenia. Int. Clin. Psychopharmacol. 2003, 18:323-329.
60. Suzuki T., Uchida H., Watanabe K., Kashima H. Treatment target in schizophrenia: a critical review and a clinical suggestion. Psychopharmacol. Bull. 2008, 41:80-102.
61. Suzuki T., Uchida H., Nomura K., Takeuchi H., Nakajima S., Tanabe A., Yagi G., Watanabe K., Kashima H. Novel rating scales for schizophrenia - Targeted Inventory on Problems in Schizophrenia (TIP-Sz) and Functional Assessment for Comprehensive Treatment of Schizophrenia (FACT-Sz). Schizophr. Res. 2008, 106:328-336.
62. Suzuki T., Uchida H., Takeuchi H., Nakajima S., Nomura K., Tanabe A., Yagi G., Watanabe K., Kashima H. Augmentation of atypical antipsychotics with valproic acid. An open-label study for most difficult patients with schizophrenia. Hum. Psychopharmacol. 2009, 24:628-638.
63. Suzuki T., Takeuchi H., Nakajima S., Nomura K., Uchida H., Yagi G., Watanabe K., Kashima H. Magnitude of rater differences in assessment scales for schizophrenia. J. Clin. Psychopharmacol. 2010, 30:607-611.
64. Suzuki T., Remington G., Arenovich T., Uchida H., Agid O., Graff-Guerrero A., Mamo D.C. Time course of improvement with antipsychotic medication in treatment-resistant schizophrenia. Br. J. Psychiatry. 2011, 199:275-280. 10.1192/bjp.bp. 110.083907.
65. Tollefson G.D., Birkett M.A., Kiesler G.M., Wood A.J. Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biol. Psychiatry 2001, 49:52-63. Lilly Resistant Schizophrenia Study Group.
66. Tsang H.W., Leung A.Y., Chung R.C., Bell M., Cheung W.M. Review on vocational predictors: a systematic review of predictors of vocational outcomes among individuals with schizophrenia: an update since 1998. Aust. N. Z. J. Psychiatry 2010, 44:495-504.
67. Volavka J., Czobor P., Sheitman B., Lindenmayer J.P., Citrome L., McEvoy J.P., Cooper T.B., Chakos M., Lieberman J.A. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am. J. Psychiatry 2002, 159:255-262.
68. Wheeler A., Humberstone V., Robinson G. Outcomes for schizophrenia patients with clozapine treatment: how good does it get?. J. Psychopharmacol. 2009, 23:957-965.
69. Wirshing D.A., Marshall B.D., Green M.F., Mintz J., Marder S.R., Wirshing W.C. Risperidone in treatment-refractory schizophrenia. Am. J. Psychiatry 1999, 156:1374-1379.
70. Zhang X.Y., Zhou D.F., Cao L.Y., Zhang P.Y., Wu G.Y., Shen Y.C. Risperidone versus haloperidol in the treatment of acute exacerbations of chronic inpatients with schizophrenia: a randomized double-blind study. Int. Clin. Psychopharmacol. 2001, 16:325-330.
71. Zhang X.Y., Zhou D.F., Zhang P.Y., Wu G.Y., Su J.M., Cao L.Y. A double-blind, placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia. J. Clin. Psychiatry 2001, 62:878-883.
72. Zhang Z.J., Kang W.H., Li Q., Wang X.Y., Yao S.M., Ma A.Q. Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: a double-blind, randomized, placebo-controlled study. Schizophr. Res. 2006, 88:102-110.
73. Zito J.M., Volavka J., Craig T.J., Czobor P., Banks S., Vitrai J. Pharmacoepidemiology of clozapine in 202 inpatients with schizophrenia. Ann. Pharmacother. 1993, 27:1262-1269.